Literature DB >> 6186603

Presence of an abnormal beta 2-microglobulin mRNA in Daudi cells: induction by interferon.

F Rosa, M Fellous, M Dron, M Tovey, M Revel.   

Abstract

Human alpha and beta interferons increase the amount of class I human histocompatibility messenger RNA HLA-A, B, C and beta 2-microglobulin in most human cells studied to date. This report concerns the effect of interferons on the Burkitt lymphoma-derived cell line Daudi, which does not express HLA-A, B, C antigens or beta 2-microglobulin on its membrane. HLA-A, B, C messenger RNA present in Daudi cells is increased by both alpha and beta interferons. Furthermore, we have shown that although it was not possible to detect mature beta 2-microglobulin protein in the cytoplasm or on the cell membrane of Daudi cells, a poly A+ messenger RNA is present in Daudi cells, which hybridizes with a cDNA clone specific for human beta 2-microglobulin. This abnormal messenger RNA is, however, increased normally by interferon. These effects were also observed with human interferon beta on a variant of Daudi cells characterized by a markedly reduced sensitivity to anti-proliferative and anti-cellular effects of human interferon alpha.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186603     DOI: 10.1007/bf00364752

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  15 in total

1.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

2.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

4.  Absence of significant H-2 and beta 2-microglobulin mRNA expression by mouse embryonal carcinoma cells.

Authors:  D Morello; F Daniel; P Baldacci; Y Cayre; G Gachelin; P Kourilsky
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

5.  Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.

Authors:  M Fellous; U Nir; D Wallach; G Merlin; M Rubinstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin.

Authors:  S V Suggs; R B Wallace; T Hirose; E H Kawashima; K Itakura
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

7.  The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin.

Authors:  B Arce-Gomez; E A Jones; C J Barnstable; E Solomon; W F Bodmer
Journal:  Tissue Antigens       Date:  1978-02

8.  Molecular cloning of a human histocompatibility antigen cDNA fragment.

Authors:  H L Ploegh; H T Orr; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  Identification of the translation products of human fibroblast interferon mRNA in reticulocyte lysates.

Authors:  J Weissenbach; M Zeevi; T Landau; M Revel
Journal:  Eur J Biochem       Date:  1979-07

10.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06
View more
  12 in total

Review 1.  IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.

Authors:  M Hokland; P Basse; J Justesen; P Hokland
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

2.  Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens.

Authors:  R DeMars; R Rudersdorf; C Chang; J Petersen; J Strandtmann; N Korn; B Sidwell; H T Orr
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

Review 3.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

4.  3' end structure of the human (2'-5') oligo A synthetase gene: prediction of two distinct proteins with cell type-specific expression.

Authors:  P Benech; G Merlin; M Revel; J Chebath
Journal:  Nucleic Acids Res       Date:  1985-02-25       Impact factor: 16.971

5.  Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon.

Authors:  L A Lampson; C A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

6.  Receptor mediated pathways for interferon action: in vivo implications.

Authors:  K E Mogensen; M T Bandu; F Vignaux; G Uze; P Eid
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Selective reduction of c-myc mRNA in Daudi cells by human beta interferon.

Authors:  G J Jonak; E Knight
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression.

Authors:  P Möller; B Lämmler; B Herrmann; H F Otto; G Moldenhauer; F Momburg
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

Review 9.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

10.  Interaction of Platelet-Derived Microparticles with a Human B-Lymphoblast Cell Line: A Clue for the Immunologic Function of the Microparticles.

Authors:  Fatemah Yari; Mahboubeh Motefaker; Mahin Nikougoftar; Zahra Khayati
Journal:  Transfus Med Hemother       Date:  2017-09-26       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.